Augmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptors

Tim J. Kruser, Deric L. Wheeler, Eric A. Armstrong, Mari Iida, Kevin R. Kozak, Albert J. Van Der Kogel, Johan Bussink, Angela Coxon, Anthony Polverino, Paul M. Harari

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Background: Motesanib is a potent inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, platelet-derived growth factor receptor, and Kit receptors. In this report we examine the interaction between motesanib and radiation in vitro and in head and neck squamous cell carcinoma (HNSCC) xenograft models. Experimental Design: In vitro assays were done to assess the impact of motesanib on VEGFR2 signaling pathways in human umbilical vein endothelial cells (HUVEC). HNSCC lines grown as tumor xenografts in athymic nude mice were utilized to assess the in vivo activity of motesanib alone and in combination with radiation. Results: Motesanib inhibited VEGF-stimulated HUVEC proliferation in vitro, as well as VEGFR2 kinase activity. Additionally, motesanib and fractionated radiation showed additive inhibitory effects on HUVEC proliferation. In vivo combination therapy with motesanib and radiation showed increased response compared with drug or radiation alone in UM-SCC1 (P < 0.002) and SCC-1483 xenografts (P = 0.001); however, the combination was not significantly more efficacious than radiation alone in UM-SCC6 xenografts. Xenografts treated with motesanib showed a reduction of vessel penetration into tumor parenchyma, compared with control tumors. Furthermore, triple immunohistochemical staining for vasculature, proliferation, and hypoxia showed well-defined spatial relationships among these parameters in HNSCC xenografts. Motesanib significantly enhanced intratumoral hypoxia in the presence and absence of fractionated radiation. Conclusions: These studies identify a favorable interaction when combining radiation and motesanib in HNSCC models. The data presented suggest that motesanib reduces blood vessel penetration into tumors and thereby increases intratumoral hypoxia. These findings suggest that clinical investigations examining combinations of radiation and motesanib are warranted in HNSCC.

Original languageEnglish (US)
Pages (from-to)3639-3647
Number of pages9
JournalClinical Cancer Research
Volume16
Issue number14
DOIs
StatePublished - Jul 15 2010

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Augmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptors'. Together they form a unique fingerprint.

Cite this